$REGN
REGENERON PHARMACEUTICALS, INC. Stock $regn

$regn Overview Financials Valuation SEC Filings Company Website

2017 Q1 Form 10-Q Financial Statement

#000153217617000017 Filed on May 04, 2017

Income Statement

Concept	2017 Q1	2016 Q1
Revenue	$1.319B	$1.201B
YoY Change	9.84%	38.09%
Cost Of Revenue	$61.25M	$78.94M
YoY Change	-22.41%	85.44%
Gross Profit	$1.258B	$1.122B
YoY Change	12.11%	35.65%
Gross Profit Margin	95.36%	93.43%
Selling, General & Admin	$296.8M	$289.7M
YoY Change	2.47%	82.2%
% of Gross Profit	23.6%	25.82%
Research & Development	$507.4M	$470.1M
YoY Change	7.94%	37.01%
% of Gross Profit	40.35%	41.9%
Depreciation & Amortization	$38.12M	$22.98M
YoY Change	65.88%	43.36%
% of Gross Profit	3.03%	2.05%
Operating Expenses	$804.3M	$759.8M
YoY Change	5.86%	51.32%
Operating Profit	$430.5M	$329.3M
YoY Change	30.74%	16.14%
Interest Expense	$7.501M	-$2.640M
YoY Change	-384.13%	-142.79%
% of Operating Profit	1.74%	-0.8%
Other Income/Expense, Net	$1.747M	$843.0K
YoY Change	107.24%	-111.99%
Pretax Income	$432.3M	$330.2M
YoY Change	30.94%	19.39%
Income Tax	$183.4M	$148.8M
% Of Pretax Income	42.42%	45.06%
Net Earnings	$248.9M	$181.4M
YoY Change	37.22%	138.6%
Net Earnings / Revenue	18.87%	15.1%
Basic Earnings Per Share	$2.36	$1.74
Diluted Earnings Per Share	$2.16	$1.59
COMMON SHARES
Basic Shares Outstanding	105.6M shares	104.3M shares
Diluted Shares Outstanding	115.1M shares	114.2M shares

Balance Sheet

Concept	2017 Q1	2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.307B	$849.0M
YoY Change	53.95%	14.42%
Cash & Equivalents	$811.8M	$604.2M
Short-Term Investments	$495.0M	$245.0M
Other Short-Term Assets	$291.0M	$162.0M
YoY Change	79.63%	29.6%
Inventory	$466.6M	$303.3M
Prepaid Expenses
Receivables	$1.340B	$1.451B
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$3.669B	$3.133B
YoY Change	17.1%	35.6%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.277B	$1.666B
YoY Change	36.64%	50.04%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$968.0M	$555.0M
YoY Change	74.41%	14.91%
Other Assets	$37.09M	$5.791M
YoY Change	540.42%	29.47%
Total Long-Term Assets	$4.148B	$2.771B
YoY Change	49.69%	46.78%
TOTAL ASSETS
Total Short-Term Assets	$3.669B	$3.133B
Total Long-Term Assets	$4.148B	$2.771B
Total Assets	$7.817B	$5.904B
YoY Change	32.4%	40.63%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$142.0M	$121.0M
YoY Change	17.36%	32.97%
Accrued Expenses	$469.0M	$469.0M
YoY Change	0.0%	26.08%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$7.000M
YoY Change
Total Short-Term Liabilities	$1.308B	$919.7M
YoY Change	42.25%	71.55%
LONG-TERM LIABILITIES
Long-Term Debt	$700.0M	$362.0M
YoY Change	93.37%	-23.31%
Other Long-Term Liabilities	$106.2M	$121.0M
YoY Change	-12.19%	117.77%
Total Long-Term Liabilities	$106.2M	$121.0M
YoY Change	-12.19%	117.77%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.308B	$919.7M
Total Long-Term Liabilities	$106.2M	$121.0M
Total Liabilities	$2.951B	$2.139B
YoY Change	37.95%	74.34%
SHAREHOLDERS EQUITY
Retained Earnings	$1.997B	$1.018B
YoY Change	96.1%	247.99%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)	$316.2M	$307.5M
YoY Change	2.85%	69.11%
Treasury Stock Shares	3.764M shares	3.660M shares
Shareholders Equity	$4.866B	$3.765B
YoY Change
Total Liabilities & Shareholders Equity	$7.817B	$5.904B
YoY Change	32.4%	40.63%

Cashflow Statement

Concept	2017 Q1	2016 Q1
OPERATING ACTIVITIES
Net Income	$248.9M	$181.4M
YoY Change	37.22%	138.6%
Depreciation, Depletion And Amortization	$38.12M	$22.98M
YoY Change	65.88%	43.36%
Cash From Operating Activities	$355.9M	$44.99M
YoY Change	691.08%	-144.23%
INVESTING ACTIVITIES
Capital Expenditures	-$50.50M	-$104.1M
YoY Change	-51.49%	-8.84%
Acquisitions
YoY Change
Other Investing Activities	-$89.70M	$60.40M
YoY Change	-248.51%	-494.77%
Cash From Investing Activities	-$140.1M	-$43.69M
YoY Change	220.8%	-66.26%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$16.67M	$39.30M
YoY Change	-57.58%	-48.47%
Debt Paid & Issued, Net	$12.86M	$598.0K
YoY Change	2050.67%
Cash From Financing Activities	$60.81M	-$206.2M
YoY Change	-129.49%	-328.1%
NET CHANGE
Cash From Operating Activities	$355.9M	$44.99M
Cash From Investing Activities	-$140.1M	-$43.69M
Cash From Financing Activities	$60.81M	-$206.2M
Net Change In Cash	$276.6M	-$204.9M
YoY Change	-234.99%	45.5%
FREE CASH FLOW
Cash From Operating Activities	$355.9M	$44.99M
Capital Expenditures	-$50.50M	-$104.1M
Free Cash Flow	$406.4M	$149.1M
YoY Change	172.59%	1095.29%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q1	dei	Amendment Flag AmendmentFlag	false
CY2017Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2017Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2017Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
CY2017Q1	dei	Document Period End Date DocumentPeriodEndDate	2017-03-31
CY2017Q1	dei	Document Type DocumentType	10-Q
CY2017Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000872589
CY2017Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2017Q1	dei	Entity Registrant Name EntityRegistrantName	REGENERON PHARMACEUTICALS INC
CY2015Q4	regn	Accrued Capital Expenditures AccruedCapitalExpenditures	56200000	USD
CY2016Q1	regn	Accrued Capital Expenditures AccruedCapitalExpenditures	84100000	USD
CY2016Q4	regn	Accrued Capital Expenditures AccruedCapitalExpenditures	28200000	USD
CY2017Q1	regn	Accrued Capital Expenditures AccruedCapitalExpenditures	32300000	USD
CY2016Q4	regn	Accrued Clinical Trial Expense Current AccruedClinicalTrialExpenseCurrent	91753000	USD
CY2016Q4	regn	Capitalandfacilityleaseobligationscurrent Capitalandfacilityleaseobligationscurrent	129557000	USD
CY2017Q1	regn	Accrued Clinical Trial Expense Current AccruedClinicalTrialExpenseCurrent	92474000	USD
CY2016Q4	regn	Accruedsalesrelatedchargesdeductionsandroyalties Accruedsalesrelatedchargesdeductionsandroyalties	159985000	USD
CY2017Q1	regn	Accruedsalesrelatedchargesdeductionsandroyalties Accruedsalesrelatedchargesdeductionsandroyalties	183561000	USD
CY2017Q1	regn	Aggregatefundingadvancedbytheparticipants Aggregatefundingadvancedbytheparticipants	720000000	USD
CY2016Q1	regn	Debt Conversion DebtConversion	1700000	USD
CY2016Q4	regn	Deferred Revenue From Related Party Current DeferredRevenueFromRelatedPartyCurrent	115267000	USD
CY2017Q1	regn	Capitalandfacilityleaseobligationsnoncurrent Capitalandfacilityleaseobligationsnoncurrent	700407000	USD
CY2016Q1	regn	Costofmanufacturing Costofmanufacturing	32810000	USD
CY2017Q1	regn	Costofmanufacturing Costofmanufacturing	22915000	USD
CY2017Q1	regn	Capitalandfacilityleaseobligationscurrent Capitalandfacilityleaseobligationscurrent	7200000	USD
CY2016Q4	regn	Capitalandfacilityleaseobligationsnoncurrent Capitalandfacilityleaseobligationsnoncurrent	351569000	USD
CY2017Q1	regn	Deferred Revenue From Related Party Current DeferredRevenueFromRelatedPartyCurrent	112161000	USD
CY2016Q4	regn	Deferred Revenue From Related Party Noncurrent DeferredRevenueFromRelatedPartyNoncurrent	503474000	USD
CY2017Q1	regn	Deferred Revenue From Related Party Noncurrent DeferredRevenueFromRelatedPartyNoncurrent	520191000	USD
CY2016Q4	regn	Facility Purchase Price FacilityPurchasePrice	720000000	USD
CY2016Q1	regn	Incremental Common Shares Attributable To Nonvested Restricted Shares IncrementalCommonSharesAttributableToNonvestedRestrictedShares	469000	shares
CY2017Q1	regn	Incremental Common Shares Attributable To Nonvested Restricted Shares IncrementalCommonSharesAttributableToNonvestedRestrictedShares	484000	shares
CY2017Q1	regn	Initialtermoflease Initialtermoflease	P5Y
CY2017Q1	regn	Loss Contingency Damages Soughtperunitproduced. LossContingencyDamagesSoughtperunitproduced.	10000	EUR
CY2016Q1	regn	Other Collaboration Revenue OtherCollaborationRevenue	179592000	USD
CY2017Q1	regn	Other Collaboration Revenue OtherCollaborationRevenue	193939000	USD
CY2016Q4	regn	Paymenttowardspurchasepriceof Tarrytownfacility PaymenttowardspurchasepriceofTarrytownfacility	57000000	USD
CY2017Q1	regn	Potentialextendedtermoflease Potentialextendedtermoflease	P5Y
CY2017Q1	regn	Reimbursementreceivedbythe Company ReimbursementreceivedbytheCompany	57000000	USD
CY2017Q1	regn	Tarrytownfacilitycapitalandfacilityleaseobligations Tarrytownfacilitycapitalandfacilityleaseobligations	720000000	USD
CY2016Q4	us-gaap	Accounts And Notes Receivable Net AccountsAndNotesReceivableNet	175263000	USD
CY2017Q1	us-gaap	Accounts And Notes Receivable Net AccountsAndNotesReceivableNet	195485000	USD
CY2016Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	879096000	USD
CY2017Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1061777000	USD
CY2016Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	134984000	USD
CY2017Q1	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	141801000	USD
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1343368000	USD
CY2017Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1339794000	USD
CY2016Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	92989000	USD
CY2017Q1	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	214269000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-12840000	USD
CY2017Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-5884000	USD
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3029993000	USD
CY2017Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3190882000	USD
CY2016Q1	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	-136396000	USD
CY2017Q1	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	106970000	USD
CY2016Q4	us-gaap	Assets Assets	6973466000	USD
CY2017Q1	us-gaap	Assets Assets	7817365000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	3180188000	USD
CY2017Q1	us-gaap	Assets Current AssetsCurrent	3669263000	USD
CY2016Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	1367741000	USD
CY2017Q1	us-gaap	Available For Sale Securities AvailableForSaleSecurities	1463006000	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	6241000	USD
CY2017Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	9827000	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	18987000	USD
CY2017Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	15619000	USD
CY2016Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	1380487000	USD
CY2017Q1	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	1468798000	USD
CY2016Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	58000	USD
CY2017Q1	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	27000	USD
CY2016Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss	18987000	USD
CY2017Q1	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss	15619000	USD
CY2016Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	920357000	USD
CY2017Q1	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	912165000	USD
CY2016Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	18929000	USD
CY2017Q1	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	15592000	USD
CY2016Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	883950000	USD
CY2017Q1	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	894533000	USD
CY2016Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue	36407000	USD
CY2017Q1	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue	17632000	USD
CY2016Q4	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue	0	USD
CY2017Q1	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue	15000000	USD
CY2016Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	815040000	USD
CY2017Q1	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	898045000	USD
CY2016Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	503482000	USD
CY2017Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	495311000	USD
CY2016Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1318522000	USD
CY2017Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1408356000	USD
CY2016Q1	us-gaap	Available For Sale Securities Income Tax Expense On Change In Unrealized Holding Gain Or Loss AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss	2000000.0	USD
CY2017Q1	us-gaap	Available For Sale Securities Income Tax Expense On Change In Unrealized Holding Gain Or Loss AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss	0	USD
CY2016Q1	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	0	USD
CY2017Q1	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	201200000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	809102000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	604214000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	535203000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	811773000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-204888000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	276570000	USD
CY2016Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	177177000	USD
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	255887000	USD
CY2016Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	78942000	USD
CY2017Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	61253000	USD
CY2016Q1	us-gaap	Costs And Expenses CostsAndExpenses	871541000	USD
CY2017Q1	us-gaap	Costs And Expenses CostsAndExpenses	888449000	USD
CY2016Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	116397000	USD
CY2017Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	126257000	USD
CY2016Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	327298000	USD
CY2017Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	316227000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Liabilities Net Noncurrent DeferredTaxAssetsLiabilitiesNetNoncurrent	825303000	USD
CY2017Q1	us-gaap	Deferred Tax Assets Liabilities Net Noncurrent DeferredTaxAssetsLiabilitiesNetNoncurrent	866291000	USD
CY2016Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	22977000	USD
CY2017Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	38115000	USD
CY2016Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.74
CY2017Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.36
CY2016Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.59
CY2016Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.451
CY2017Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.16
CY2017Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.424
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	153086000	USD
CY2017Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	94088000	USD
CY2016Q1	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2017Q1	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2016Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3	0	USD
CY2017Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3	0	USD
CY2016Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3	0	USD
CY2017Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3	0	USD
CY2016Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	330151000	USD
CY2017Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	432289000	USD
CY2016Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	148766000	USD
CY2017Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	183358000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	103431000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	187695000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	397428000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	137928000	USD
CY2016Q1	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	79785000	USD
CY2017Q1	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	40988000	USD
CY2016Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	91205000	USD
CY2017Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	12400000	USD
CY2016Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	62263000	USD
CY2017Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	69744000	USD
CY2016Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-39260000	USD
CY2017Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	20325000	USD
CY2016Q1	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	1278000	shares
CY2017Q1	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2016Q1	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	44000	shares
CY2017Q1	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
CY2016Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	8147000	shares
CY2017Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	9050000	shares
CY2016Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-2640000	USD
CY2017Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-7501000	USD
CY2016Q1	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	56000	USD
CY2017Q1	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	0	USD
CY2016Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	13334000	USD
CY2017Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	20259000	USD
CY2016Q4	us-gaap	Inventory Net InventoryNet	399356000	USD
CY2017Q1	us-gaap	Inventory Net InventoryNet	466576000	USD
CY2016Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	92287000	USD
CY2017Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	127637000	USD
CY2016Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	202301000	USD
CY2017Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	173469000	USD
CY2016Q1	us-gaap	Inventory Write Down InventoryWriteDown	4300000	USD
CY2017Q1	us-gaap	Inventory Write Down InventoryWriteDown	6400000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	2524221000	USD
CY2017Q1	us-gaap	Liabilities Liabilities	2951344000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6973466000	USD
CY2017Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7817365000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1241495000	USD
CY2017Q1	us-gaap	Liabilities Current LiabilitiesCurrent	1308271000	USD
CY2017Q1	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	10000000	EUR
CY2016Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	503481000	USD
CY2017Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	495311000	USD
CY2016Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	864260000	USD
CY2017Q1	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	967695000	USD
CY2016Q1	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	0	USD
CY2017Q1	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	0	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-206192000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	60812000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-43685000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-140143000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	44989000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	355901000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	181385000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	248931000	USD
CY2016Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	181441000	USD
CY2017Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	248931000	USD
CY2016Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	843000	USD
CY2017Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1747000	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	329308000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	430542000	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	103512000	USD
CY2017Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	99048000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	20294000	USD
CY2017Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	37087000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	0	USD
CY2016Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-4208000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	6956000	USD
CY2016Q4	us-gaap	Other Inventory Net Of Reserves OtherInventoryNetOfReserves	91434000	USD
CY2017Q1	us-gaap	Other Inventory Net Of Reserves OtherInventoryNetOfReserves	145211000	USD
CY2016Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1178000	USD
CY2017Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	876000	USD
CY2016Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	100385000	USD
CY2017Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	106248000	USD
CY2016Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-3957000	USD
CY2017Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-3956000	USD
CY2016Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3483000	USD
CY2017Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	9248000	USD
CY2016Q1	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	17381000	USD
CY2017Q1	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	56440000	USD
CY2016Q1	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	242117000	USD
CY2017Q1	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	0	USD
CY2016Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1042000	USD
CY2017Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	USD
CY2016Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	USD
CY2017Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	208694000	USD
CY2016Q1	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	104094000	USD
CY2017Q1	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	50461000	USD
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2017Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	30000000	shares
CY2017Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	30000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	130528000	USD
CY2017Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	146055000	USD
CY2016Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	39304000	USD
CY2017Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	16673000	USD
CY2016Q1	us-gaap	Proceeds From Repayments Of Long Term Debt And Capital Securities ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities	0	USD
CY2017Q1	us-gaap	Proceeds From Repayments Of Long Term Debt And Capital Securities ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities	57000000	USD
CY2016Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	60409000	USD
CY2017Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	119012000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2083421000	USD
CY2017Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2277029000	USD
CY2016Q1	us-gaap	Realized Gain Loss On Marketable Securities And Cost Method Investments Excluding Other Than Temporary Impairments And Other Investments RealizedGainLossOnMarketableSecuritiesAndCostMethodInvestmentsExcludingOtherThanTemporaryImpairmentsAndOtherInvestments	0	USD
CY2016Q1	us-gaap	Realized Gain Loss On Marketable Securities Cost Method Investments And Other Investments RealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments	0	USD
CY2016Q1	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	1739000	USD
CY2017Q1	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	USD
CY2016Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	598000	USD
CY2017Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	12861000	USD
CY2016Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	470112000	USD
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	507435000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	1748222000	USD
CY2017Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	1997153000	USD
CY2016Q1	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	219694000	USD
CY2017Q1	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	210367000	USD
CY2016Q1	us-gaap	Revenues Revenues	1200849000	USD
CY2017Q1	us-gaap	Revenues Revenues	1318991000	USD
CY2016Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	784182000	USD
CY2017Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	858245000	USD
CY2016Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	289677000	USD
CY2017Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	296846000	USD
CY2016Q1	us-gaap	Share Based Compensation ShareBasedCompensation	142250000	USD
CY2017Q1	us-gaap	Share Based Compensation ShareBasedCompensation	133789000	USD
CY2016Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	16774	shares
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	4449245000	USD
CY2017Q1	us-gaap	Stockholders Equity StockholdersEquity	4866021000	USD
CY2016Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	235776000	USD
CY2017Q1	us-gaap	Taxes Payable Current TaxesPayableCurrent	450805000	USD
CY2016Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	3763868	shares
CY2017Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	3763868	shares
CY2016Q4	us-gaap	Treasury Stock Value TreasuryStockValue	316240000	USD
CY2017Q1	us-gaap	Treasury Stock Value TreasuryStockValue	316240000	USD
CY2015Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	55249000	USD
CY2016Q1	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	42465000	USD
CY2016Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	45851000	USD
CY2017Q1	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	56033000	USD
CY2016Q1	us-gaap	Valuation Allowances And Reserves Charged To Other Accounts ValuationAllowancesAndReservesChargedToOtherAccounts	57583000	USD
CY2017Q1	us-gaap	Valuation Allowances And Reserves Charged To Other Accounts ValuationAllowancesAndReservesChargedToOtherAccounts	89603000	USD
CY2016Q1	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	70367000	USD
CY2017Q1	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	79421000	USD
CY2016Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	9938000	shares
CY2017Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	9534000	shares
CY2016Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	114228000	shares
CY2017Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	115106000	shares
CY2016Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	104290000	shares
CY2017Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	105572000	shares
CY2017Q1	us-gaap	Description Of New Accounting Pronouncements Not Yet Adopted DescriptionOfNewAccountingPronouncementsNotYetAdopted	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Recently Issued Accounting Standards </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued Accounting Standards Update 2014-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;">, which will replace existing revenue recognition guidance. The new standard requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. To achieve that core principle, an entity must identify the contract(s) with a customer, identify the performance obligations in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract, and recognize revenue when (or as) the entity satisfies the performance obligation. In July 2015, the FASB decided to delay the effective date of the new standard by one year; as a result, the new standard will be effective for annual and interim reporting periods beginning after December 15, 2017. Early adoption will be permitted, but no earlier than 2017 for calendar year-end entities. The standard allows for two transition methods - retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying the standard recognized at the date of initial adoption. The Company has not yet determined its method of transition. The Company does not expect the new standard to have a material impact on the recognition of revenue from product sales. However, the Company continues to evaluate the impact that this guidance will have on its financial statements in connection with collaboration and license agreements.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2016, the FASB issued Accounting Standards Update 2016-01, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recognition and Measurement of Financial Assets and Financial Liabilities</font><font style="font-family:inherit;font-size:10pt;">. The amendments require equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income. The amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. The implementation of the amendments is expected to increase the volatility of an entity's net income; however, the Company is not currently able to estimate the impact of adopting these amendments, as the significance of the impact will depend on the Company's equity investment balance upon adoption.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued Accounting Standards Update 2016-02, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;">. The new standard requires a lessee to recognize in its balance sheet (for both finance and operating leases) a liability to make lease payments and a right-of-use asset representing its right to use the underlying asset for the lease term. The amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted. The Company is evaluating the impact that this guidance will have on the Company's financial statements.</font></div></div>
CY2017Q1	us-gaap	Revenue Recognition Revenue Reductions RevenueRecognitionRevenueReductions	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from product sales is recorded net of applicable provisions for rebates and chargebacks, distribution-related fees, and other sales-related deductions. </font></div></div>

Files In Submission

Name	View Source	Status
0001532176-17-000017-index-headers.html	Edgar Link	pending
0001532176-17-000017-index.html	Edgar Link	pending
0001532176-17-000017.txt	Edgar Link	pending
0001532176-17-000017-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
regn-033117x10q.htm	Edgar Link	pending
regn-20170331.xml	Edgar Link	completed
regn-20170331.xsd	Edgar Link	pending
regn-20170331_cal.xml	Edgar Link	unprocessable
regn-20170331_def.xml	Edgar Link	unprocessable
regn-20170331_lab.xml	Edgar Link	unprocessable
regn-20170331_pre.xml	Edgar Link	unprocessable
regn-ex_311x03312017x10q.htm	Edgar Link	pending
regn-ex_312x03312017x10q.htm	Edgar Link	pending
regn-ex_32x03312017x10q.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$REGN
REGENERON PHARMACEUTICALS, INC. Stock $regn

2017 Q1 Form 10-Q Financial Statement

#000153217617000017 Filed on May 04, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$REGN REGENERON PHARMACEUTICALS, INC. Stock $regn

2017 Q1 Form 10-Q Financial Statement

#000153217617000017 Filed on May 04, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$REGN
REGENERON PHARMACEUTICALS, INC. Stock $regn